Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus

by Dejager S, Schweizer A, Foley JE
Published 2012-05-01

Blood pressure and fasting lipid changes after 24 weeks’ treatment with vildagliptin: a pooled analysis in >2,000 previously drug-naïve patients with type 2 diabetes...

by Evans M, Schweizer A, Foley JE
Published 2016-08-01

Does the treatment of type 2 diabetes mellitus with the DPP-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients?

by Foley JE, Bhosekar V, Kawamori R
Published 2016-01-01

DPP-4 inhibitor treatment: β-cell response but not HbA1c reduction is dependent on the duration of diabetes

by Kozlovski P, Bhosekar V, Foley JE
Published 2017-03-01

Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies

by Schweizer A, Dejager S, Foley JE, Kothny W
Published 2011-02-01

Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes

by Blüher M, Schweizer A, Bader G, Foley JE
Published 2014-11-01

Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment

by Lukashevich V, Schweizer A, Foley JE, Dickinson S, Groop PH, Kothny W
Published 2013-01-01

Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin

by Schweizer A, Foley JE, Kothny W, Ahrén B
Published 2013-02-01